Asthma
Conditions
Brief summary
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
Detailed description
Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro,
Interventions
DIAGNOSTIC_TESTFeNO measurement
FeNO measurement at each visit
Sponsors
Bosch Healthcare Solutions GmbH
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
7 Years to 80 Years
Inclusion criteria
1. Subject is 7 to 80 years of age. 2. Has asthma 3. Has been identified as a candidate for inhaled corticosteroid (ICS) treatment 4. Is willing and able to perform Vivatmo pro™ testing
Exclusion criteria
1. Subject has used corticosteroids prior to enrollment. 2. Subject has other current serious medical conditions 3. Subject has not been clinically stable for at least 2 weeks prior to the study 4. Subject is unwilling or unable to perform Vivatmo pro testing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in FeNO Value [Time Frame: 14 days] | 14 days | Change in FeNO value before and after inhaled corticosteroid treatment |
Countries
Czechia, Germany
Outcome results
None listed